Inventor · disambiguated record
Mallikarjuna Reddy Putta
Also filed as: PUTTA MALLIKARJUNA · PUTTA MALLIKARJUNA R · PUTTA MALLIKARJUNA REDDY
18 granted patents·33 pending applications·167 citations·filing 2006–2025
94Inventor score
Files withKORRO BIO INC27IDERA PHARMACEUTICALS INC15KANDIMALLA EKAMBAR4AGRAWAL SUDHIR3KANDIMALLA EKAMBAR R2
Top patents by PatentIndex Score
51 records- 0196US8431544B1Compositions for inhibiting gene expression and uses thereofAGRAWAL SUDHIR·Filed 2010·Granted Apr 30, 2013·48 cites·16 claims
- 0295US11479575B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2020·Granted Oct 25, 2022·5 cites·17 claims
- 0394US11453878B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2020·Granted Sep 27, 2022·5 cites·18 claims
- 0493US12031131B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2023·Granted Jul 9, 2024·1 cites·27 claims
- 0592US12448620B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2022·Granted Oct 21, 2025·1 cites·20 claims
- 0692US12173285B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2023·Granted Dec 24, 2024·1 cites·28 claims
- 0792US12152050B2RNA-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2022·Granted Nov 26, 2024·1 cites·17 claims
- 0892US7960362B2Synthetic agonists of TLR9IDERA PHARMACEUTICALS INC·Filed 2008·Granted Jun 14, 2011·19 cites·6 claims
- 0991US8361986B2Synthetic agonists of TLR9IDERA PHARMACEUTICALS INC·Filed 2011·Granted Jan 29, 2013·18 cites·6 claims
- 1091US7786089B2Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segmentsIDERA PHARMACEUTICALS INC·Filed 2006·Granted Aug 31, 2010·14 cites·8 claims
- 1190US8853375B2Toll like receptor modulatorsKANDIMALLA EKAMBAR·Filed 2008·Granted Oct 7, 2014·17 cites·7 claims
- 1290US7884197B2Synthetic agonists of TLR9IDERA PHARMACEUTICALS INC·Filed 2007·Granted Feb 8, 2011·13 cites·5 claims
- 1387US8106173B2Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8KANDIMALLA EKAMBAR R·Filed 2007·Granted Jan 31, 2012·9 cites·14 claims
- 1486US9243050B2Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8IDERA PHARMACEUTICALS INC·Filed 2014·Granted Jan 26, 2016·7 cites·20 claims
- 1585US2025382610A1Rna-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2025·Application pending·0 cites
- 1683US2025215038A1Rna-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2024·Application pending·0 cites
- 1781US8759310B2Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8KANDIMALLA EKAMBAR R·Filed 2012·Granted Jun 24, 2014·4 cites·20 claims
- 1880US2025066773A1Rna-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2024·Application pending·0 cites
- 1979US8153777B2Modulation of toll-like receptor 5 expression by antisense oligonucleotidesKANDIMALLA EKAMBAR·Filed 2009·Granted Apr 10, 2012·3 cites·23 claims
- 2070US8877722B2Compositions for inhibiting gene expression and uses thereofAGRAWAL SUDHIR·Filed 2011·Granted Nov 4, 2014·1 cites·10 claims
- 2168US2025034563A1Methods and Compositions for ADAR-Mediated EditingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 2267US2025034564A1Methods and Compositions for ADAR-Mediated EditingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 2366US2025388903A1Methods and Compositions for Adar-Mediated EditingKORRO BIO INC·Filed 2025·Application pending·0 cites
- 2464US2023257752A1Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 2564US2023272376A1Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 2664US2023295664A1Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 2764US2023295614A1Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 2864US2023272384A1Methods and compositions for the adar-mediated editing of retinochisin 1 (rs1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 2964US2023212569A1Methods and compositions for the adar-mediated editing of otoferlin (otof)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 3064US2023272377A1Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 3164US2023272383A1Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 3263US2024263177A1Methods and Compositions for Adar-Mediated EditingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 3362US2020385713A1Rna-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2020·Application pending·0 cites
- 3462US2022307027A1RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses ThereofKORRO BIO INC·Filed 2022·Application pending·0 cites
- 3561US8153605B2Modulation of toll-like receptor 3 expression by antisense oligonucleotidesKANDIMALLA EKAMBAR·Filed 2009·Granted Apr 10, 2012·0 cites·30 claims
- 3657US2023174989A1Methods and Compositions for the ADAR-Mediated Editing of ABCA4KORRO BIO INC·Filed 2021·Application pending·0 cites
- 3757US2021380980A1Methods and Compositions for the ADAR-Mediated Editing of SERPINA1KORRO BIO INC·Filed 2021·Application pending·0 cites
- 3857US2025352667A1Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 3954US2015044196A1Compositions for Inhibiting Gene Expression and Uses ThereofIDERA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4053US2010092486A1Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4153US2010111936A1Modulation of Toll-Like Receptor 4 Expression by Antisense OligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4253US2010111935A1Modulation of Toll-Like Receptor 2 Expression By Antisense OligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4353US2010047188A1Modulation of toll-like receptor 8 expression by antisense oligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4452US2010035967A1Modulation of toll-like receptor 9 expression by antisense oligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4552US2010041734A1Modulation of toll-like receptor 7 expression by antisense oligonucleotidesIDERA PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4648US2025340876A1Rna-editing oligonucleotides and uses thereofKORRO BIO INC·Filed 2025·Application pending·0 cites
- 4746US2011135669A1Synthetic agonists of tlr9IDERA PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 4845US2012016004A1Compositions for inhibiting gene expression and uses thereofAGRAWAL SUDHIR·Filed 2011·Application pending·0 cites
- 4944US2010215646A1Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segmentsIDERA PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 5035US2011293565A1Novel synthetic agonists of tlr9KANDIMALLA EKAMBAR·Filed 2010·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →